Evidence map›Paper›PMID 39210290›Full record

ArticleBMC genomics2024

HASCH - A high-throughput amplicon-based SNP-platform for medicinal cannabis and industrial hemp genotyping applications.

Locedie Mansueto, Erwin Tandayu, Jos Mieog, Lennard Garcia-de Heer, Rekhamani Das, Adam Burn, Ramil Mauleon, Tobias Kretzschmar

Abstract read
In one paragraph

Article in BMC genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Genetic Advances inPlants (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Locedie MansuetoSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Erwin TandayuSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Jos MieogSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Lennard Garcia-de HeerSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Rekhamani DasSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Adam BurnSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Ramil MauleonSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia.
Tobias KretzschmarSouthern Cross Plant Science, Faculty of Science and Engineering, Southern Cross University, 1 Military Road, East Lismore, NSW, 2480, Australia. Tobias.Kretzschmar@scu.edu.au.

Funding

Australian Research Council LP210200606Southern Cross University PhD stipend
6 · The paper itself

Abstract

backgroundCannabis sativa is seeing a global resurgence as a food, fiber and medicinal crop for industrial hemp and medicinal Cannabis industries respectively. However, a widespread moratorium on the use and research of C. sativa throughout most of the 20th century has seen the development of improved cultivars for specific end uses lag behind that of conventional crops. While C. sativa research and development has seen significant investments in the recent past, resulting in a suite of publicly available genomic resources and tools, a versatile and cost-effective mid-density genotyping platform for applied purposes in breeding and pre-breeding is lacking. Here we report on a first mid-density fixed-target SNP platform for C. sativa.

resultsThe High-throughput Amplicon-based SNP-platform for medicinal Cannabis and industrial Hemp (HASCH) was designed using a combination of filtering and Integer Linear Programming on publicly available whole-genome sequencing and RNA sequencing data, supplemented with in-house generated genotyping-by-sequencing (GBS) data. HASCH contains 1,504 genome-wide targets of high call rate (97% mean) and even distribution across the genome, designed to be highly informative (> 0.3 minor allele frequency) across both medicinal cannabis and industrial hemp gene pools. Average numbers of mismatch SNP between any two accessions were 251 for medicinal cannabis (N = 116) and 272 for industrial hemp (N = 87). Comparing HASCH data with corresponding GBS data on a collection of diverse C. sativa accessions demonstrated high concordance and resulted in comparable phylogenies and genetic distance matrices. Using HASCH on a segregating F2 population derived from a cross between a tetrahydrocannabinol (THC)-dominant and a cannabidiol (CBD)-dominant accession resulted in a genetic map consisting of 310 markers, comprising 10 linkage groups and a total size of 582.7 cM. Quantitative Trait Locus (QTL) mapping identified a major QTL for CBD content on chromosome 7, consistent with previous findings.

conclusionHASCH constitutes a versatile, easy to use and cost-effective genotyping solution for the rapidly growing Cannabis research community. It provides consistent genetic fingerprints of 1504 SNPs with wide applicability genetic resource management, quantitative genetics and breeding.

Indexed as

CannabisGenotyping TechniquesMedical MarijuanaPolymorphism, Single NucleotideGenome, PlantGenotypeHigh-Throughput Nucleotide SequencingMedical MarijuanaCannabis sativaGenetic fingerprintsGenotypingInteger linear programmingPlant breedingQuantitative trait lociSNP

Identifiers

PMID39210290
PMCPMC11363669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.